There is still venture capital out there for early-stage biopharma firms, and some are able to secure significant chunks even at series A.
There is still venture capital out there for early-stage biopharma firms, and some are able to secure significant chunks even at series A.
Examples over the past month include:
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.
Company surprises investors with Jørgensen's exit but insists its strategy will not change.
Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.
Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.
The drug boosted overall responses on top of the R-GemOx backbone, but the discussant pointed out that patients in waveLINE-003 were not very heavily pretreated.
In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.
One Phase III trial hits but a second study misses by a mile.
